このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

AnaptysBio マネジメント

マネジメント基準チェック /34

AnaptysBio'sの CEO はDan Fagaで、 Mar2022年に任命され、の在任期間は 2.25年です。の年間総報酬は$ 7.46Mで、 8.6%給与と91.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.47%を直接所有しており、その価値は$ 9.19M 。経営陣と取締役会の平均在任期間はそれぞれ2.3年と3.3年です。

主要情報

Dan Faga

最高経営責任者

US$7.5m

報酬総額

CEO給与比率	8.6%
CEO在任期間	2.3yrs
CEOの所有権	1.5%
経営陣の平均在職期間	2.3yrs
取締役会の平均在任期間	3.3yrs

経営陣の近況

Recent updates

News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

May 22

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

May 12

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Feb 22

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Oct 10

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

May 24

Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Apr 27

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Jan 10

AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial

Oct 05

AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M

Aug 08

Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates

May 10

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Mar 16

AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest

Nov 11

AnaptysBio (NASDAQ:ANAB) Is In A Strong Position To Grow Its Business

Jul 28

Upgrade: Analysts Just Made A Dazzling Increase To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

May 09

AnaptysBio EPS beats by $0.03, beats on revenue

May 04

Industry Analysts Just Made A Huge Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts

Mar 10

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Are Pretty Bullish On The Stock After Recent Results

Feb 28

Companies Like AnaptysBio (NASDAQ:ANAB) Are In A Position To Invest In Growth

Feb 10

Why AnaptysBio's (NASDAQ:ANAB) CEO Pay Matters

Dec 19

CEO報酬分析

AnaptysBio の収益と比較して、Dan Faga の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$163m
Dec 31 2023	US$7m	US$641k	-US$164m
Sep 30 2023	n/a	n/a	-US$148m
Jun 30 2023	n/a	n/a	-US$144m
Mar 31 2023	n/a	n/a	-US$137m
Dec 31 2022	US$25m	US$474k	-US$129m
Sep 30 2022	n/a	n/a	-US$135m
Jun 30 2022	n/a	n/a	-US$108m
Mar 31 2022	n/a	n/a	-US$76m
Dec 31 2021	US$310k	n/a	-US$58m

報酬と市場: Danの総報酬 ($USD 7.46M ) は、 US市場 ($USD 3.39M ) の同規模の企業の平均を上回っています。

報酬と収益: Danの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Dan Faga (44 yo)

2.3yrs

在職期間

US$7,461,920

報酬

Mr. Daniel R. Faga, also known as Dan, is Director of Affini-T Therapeutics, Inc. from April 2022. He serves as Director at AnaptysBio, Inc. since November 2021 and is its President and Chief Executive Off...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Daniel Faga	President	2.3yrs	US$7.46m	1.47% $ 9.6m
Eric Loumeau	Chief Legal Officer	5.8yrs	US$2.26m	0.012% $ 77.8k
Paul Lizzul	Chief Medical Officer	3.9yrs	US$2.44m	0.037% $ 242.9k
Dennis Mulroy	Chief Financial Officer	3.9yrs	US$1.81m	0.0035% $ 23.1k
Beth Mueller	Senior Vice President of Human Resources	4.7yrs	データなし	データなし
Martin Dahl	Senior Vice President of Research	2.4yrs	データなし	データなし
Benjamin Stone	Chief Business Officer	less than a year	データなし	データなし
Douglas Rich	Senior Vice President of CMC	1.4yrs	データなし	データなし
Monique Da Silva	Senior Vice President of Corporate Affairs	less than a year	データなし	データなし
Priya Raina	Senior Vice President of Clinical Operations	less than a year	データなし	データなし

2.3yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: ANABの経営陣は経験豊富であると考えられます ( 2.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Daniel Faga	President	2.6yrs	US$7.46m	1.47% $ 9.6m
John Orwin	Independent Chairman of the Board	less than a year	US$338.08k	0.0075% $ 48.8k
Hollings Renton	Lead Independent Director	9yrs	US$342.38k	0.0071% $ 46.8k
John Schmid	Independent Director	9yrs	US$335.38k	0.014% $ 93.6k
Dennis Fenton	Independent Director	6.3yrs	US$331.88k	0.014% $ 93.6k
Magda Marquet	Independent Director	3.4yrs	US$318.38k	0.014% $ 93.6k
Oleg Nodelman	Independent Director	3.2yrs	データなし	データなし
J. Ware	Independent Director	6.8yrs	US$338.38k	0.027% $ 180.0k
Rita Jain	Independent Director	1.2yrs	US$495.60k	0.017% $ 108.8k
Dolca Thomas	Member of Scientific Advisory Board	1.4yrs	データなし	データなし
Luisa Salter-Cid	Member of Scientific Advisory Board	no data	データなし	データなし
John Monroe	Member of Scientific Advisory Board	no data	データなし	データなし

3.3yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: ANABの取締役会は経験豊富であると考えられます ( 3.3年の平均在任期間)。

AnaptysBio マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

AnaptysBio, Inc., Annual General Meeting, Jun 12, 2024

President recently sold US$3.4m worth of stock

Chief Legal Officer notifies of intention to sell stock

President exercised options and sold US$150k worth of stock

Chief Financial Officer exercised options and sold US$116k worth of stock

AnaptysBio, Inc. Announces Board Changes

Recent updates

News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

New minor risk - Shareholder dilution

Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 11%

AnaptysBio, Inc., Annual General Meeting, Jun 12, 2024

President recently sold US$3.4m worth of stock

Consensus revenue estimates increase by 48%

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Chief Legal Officer notifies of intention to sell stock

No longer forecast to breakeven

Price target increased by 27% to US$35.83

President exercised options and sold US$150k worth of stock

Consensus revenue estimates increase by 27%

No longer forecast to breakeven

New minor risk - Profitability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 16%

Price target decreased by 10% to US$26.80

Price target decreased by 12% to US$28.20

AnaptysBio, Inc. Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Chief Financial Officer exercised options and sold US$116k worth of stock

AnaptysBio, Inc. Announces Board Changes

High number of new directors

Consensus revenue estimates decrease by 18%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

AnaptysBio, Inc. and GSK-Partner Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approved in U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

Forecast to breakeven in 2025

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

Consensus revenue estimates fall by 43%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Forecast to breakeven in 2025

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

AnaptysBio, Inc. (NasdaqGS:ANAB) announces an Equity Buyback for $50 million worth of its shares.

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

AnaptysBio Announces Portfolio

Anaptysbio- and GSK-Partnered Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Meets Primary Endpoint in Phase 3 Ruby Trial in Primary Advanced or Recurrent Endometrial Cancer

Consensus forecasts updated

Price target increased to US$31.50

Price target increased to US$31.50

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Anaptysbio and Gsk-Partnered Immuno-Oncology Agents Jemperli (Dostarlimab-Gxly) and Cobolimab Show Positive Progress in Two Separate Non-Small Cell Lung Cancer Trials

AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial

Consensus revenue estimates increase by 58%

Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

Consensus revenue estimates increase by 17%

Price target decreased to US$29.33

AnaptysBio sells royalties from GSK-partnered Zejula for $45M

Consensus revenue estimates fall by 10%

AnaptysBio, Inc. Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa

AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans

AnaptysBio skin condition candidate fails mid-stage trial; shares down 16%

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M

High number of new directors

COO & General Counsel notifies of intention to sell stock

Price target decreased to US$31.60

Consensus revenue estimates fall by 56%

Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates

First quarter 2022 earnings: EPS and revenues miss analyst expectations

AnaptysBio, Inc., Annual General Meeting, Jun 23, 2022

Forecast to breakeven in 2024

Consensus revenue estimates increase by 86%

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

マネジメント基準チェック /34